Ko Y - Search Results

1

Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting.

Diaby V, Wang CY, Alqhtani H, van Boemmel-Wegmann S, Ali AA, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. Diaby V, et al. Among authors: ko y. Data Brief. 2020 Jan 25;29:105194. doi: 10.1016/j.dib.2020.105194. eCollection 2020 Apr. Data Brief. 2020. PMID: 32071975 Free PMC article.

2

A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.

Diaby V, Alqhtani H, van Boemmel-Wegmann S, Wang CY, Ali AA, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. Diaby V, et al. Among authors: ko y. Breast. 2020 Feb;49:141-148. doi: 10.1016/j.breast.2019.11.012. Epub 2019 Nov 26. Breast. 2020. PMID: 31805500 Free PMC article.

3

Health state utilities for metastatic breast cancer in Taiwan.

Chou TC, Chiang SC, Ko Y. Chou TC, et al. Among authors: ko y. Breast. 2020 Jun;51:57-64. doi: 10.1016/j.breast.2020.03.001. Epub 2020 Mar 6. Breast. 2020. PMID: 32213442 Free PMC article.

4

Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in treating HER-2 positive advanced breast cancer in Taiwan.

Wang LC, Kuo CN, Ko Y. Wang LC, et al. Among authors: ko y. Breast J. 2020 Oct;26(10):2099-2102. doi: 10.1111/tbj.14053. Epub 2020 Sep 17. Breast J. 2020. PMID: 32945063 No abstract available.

5

Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.

Lin YJ, Kuo CN, Ko Y. Lin YJ, et al. Among authors: ko y. Breast. 2021 Jun;57:18-24. doi: 10.1016/j.breast.2021.02.011. Epub 2021 Feb 23. Breast. 2021. PMID: 33706025 Free PMC article.

6

An evaluation of the healthcare costs associated with adverse events in patients with breast cancer.

Wang LC, Chen HM, Chen JH, Lin YC, Ko Y. Wang LC, et al. Among authors: ko y. Int J Health Plann Manage. 2021 Sep;36(5):1465-1475. doi: 10.1002/hpm.3184. Epub 2021 Apr 29. Int J Health Plann Manage. 2021. PMID: 33914358

7

An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study.

Chen HM, Chen JH, Chiang SC, Lin YC, Ko Y. Chen HM, et al. Among authors: ko y. Medicine (Baltimore). 2021 Oct 29;100(43):e27567. doi: 10.1097/MD.0000000000027567. Medicine (Baltimore). 2021. PMID: 34713830 Free PMC article.

8

Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: A systematic review and meta-analysis.

Yeh Y, Chen C, Ko Y. Yeh Y, et al. Among authors: ko y. J Cancer Res Ther. 2022 Jul-Sep;18(4):1061-1072. doi: 10.4103/jcrt.jcrt_1095_21. J Cancer Res Ther. 2022. PMID: 36149162 Free article.

9

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore.

Shih V, Chan A, Xie F, Ko Y. Shih V, et al. Among authors: ko y. Value Health Reg Issues. 2012 May;1(1):46-53. doi: 10.1016/j.vhri.2012.03.013. Epub 2012 May 25. Value Health Reg Issues. 2012. PMID: 29702826 Free article.

10

Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan.

Tseng TH, Chiang SC, Hsu JC, Ko Y. Tseng TH, et al. Among authors: ko y. PLoS One. 2024 Jun 10;19(6):e0303294. doi: 10.1371/journal.pone.0303294. eCollection 2024. PLoS One. 2024. PMID: 38857244 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,006 results

Search Page

Filters